Esperion Therapeutics Inc (NASDAQ:ESPR) CEO Timothy M. Mayleben bought 5,000 shares of the company’s stock in a transaction dated Wednesday, November 6th. The shares were purchased at an average cost of $36.98 per share, with a total value of $184,900.00. Following the acquisition, the chief executive officer now directly owns 83,663 shares of the company’s stock, valued at approximately $3,093,857.74. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
ESPR stock traded up $0.25 during midday trading on Friday, reaching $37.82. The company had a trading volume of 592,400 shares, compared to its average volume of 500,623. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of -5.02 and a beta of 1.86. The stock has a 50 day moving average price of $38.48 and a 200-day moving average price of $42.60. Esperion Therapeutics Inc has a 1-year low of $33.13 and a 1-year high of $58.90. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.65 and a quick ratio of 5.65.
Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($2.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.95) by ($0.42). The company had revenue of $0.98 million during the quarter, compared to analyst estimates of $0.99 million. During the same period in the previous year, the business posted ($1.86) earnings per share. As a group, research analysts anticipate that Esperion Therapeutics Inc will post -3.02 earnings per share for the current year.
A number of research firms have recently weighed in on ESPR. BidaskClub raised Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, October 29th. Cowen reissued a “buy” rating on shares of Esperion Therapeutics in a report on Wednesday. ValuEngine raised Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Goldman Sachs Group raised Esperion Therapeutics from a “sell” rating to a “neutral” rating and dropped their target price for the stock from $55.00 to $45.00 in a report on Monday, September 16th. Finally, Stifel Nicolaus dropped their target price on Esperion Therapeutics from $112.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday, September 17th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $70.44.
A number of hedge funds have recently bought and sold shares of ESPR. Aperio Group LLC acquired a new position in Esperion Therapeutics in the second quarter valued at about $29,000. Russell Investments Group Ltd. acquired a new position in Esperion Therapeutics in the second quarter valued at about $32,000. Tower Research Capital LLC TRC acquired a new position in Esperion Therapeutics in the third quarter valued at about $42,000. Bank of Montreal Can raised its stake in Esperion Therapeutics by 364.5% in the second quarter. Bank of Montreal Can now owns 2,671 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 2,096 shares in the last quarter. Finally, Royal Bank of Canada raised its stake in Esperion Therapeutics by 38.1% in the second quarter. Royal Bank of Canada now owns 2,938 shares of the biopharmaceutical company’s stock valued at $137,000 after purchasing an additional 811 shares in the last quarter.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
See Also: Net Asset Value
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.